Vical hopes to proceed with Phase III CMV vaccine trial after positive advice from EMA
This article was originally published in Scrip
Executive Summary
Vical, a US biopharmaceutical company, looks poised to move ahead with designing Phase III trials of its CMV (cytomegalovirus) vaccine, TransVax, after receiving positive scientific advice from the European Medicines Agency. The company is looking for a commercial partner for the vaccine in major markets in the Americas, Europe and Southeast Asia.